Life Technologies Signs Five-Year Agreement with the FDA
Collaboration will accelerate and advance food safety testing of E.coli and
CARLSBAD, Calif., July 30, 2013
CARLSBAD, Calif., July 30, 2013 /PRNewswire/ -- Life Technologies Corporation
(NASDAQ: LIFE) today announced that it has signed a five-year agreement with
the Food and Drug Administration (FDA) to accelerate and advance food safety
testing of E. coli and Salmonella, two foodborne contaminants commonly
associated with outbreaks and/or recalls.
The collaboration consists of three distinctive projects:
oLife Technologies will design and validate new food safety tests for the
detection and identification of foodborne pathogens, with pathogen strains
provided by the FDA.
oLife Technologies will design and validate a complete workflow for food
pathogen detection on the Ion PGM™ platform, while optimizing sample
oThe FDA will have the opportunity to evaluate new disruptive technology
platforms by Life Technologies for the use in pathogen detection.
Life Technologies will use its bioinformatics resources to independently
develop real-time PCR (polymerase chain reaction) assays against unique E.
coli and Salmonella targets in collaboration with the FDA. It will then
provide the test results for these targets to the FDA for further validation.
The FDA will use Life Technologies' Ion PGM™ Sequencer to generate whole
genome sequence information from defined bacteria, and for strains that will
be excluded from detection. Life Technologies' bioinformatics team will then
analyze the genomic information and provide assays or tests to the FDA for
further validation and analysis. Whole genome sequences generated under the
collaboration will be added to the National Institutes of Health Genbank so
they can be accessed by the food safety research community.
"We are excited to be entering this cooperative research and development
agreement with the FDA as we have been working alongside them in one capacity
or the other for over 10 years," said Nir Nimrodi, Vice President and General
Manager for Food Safety and Animal Health at Life Technologies. "The FDA will
call on us, particularly when it comes to developing rapid detection kits.
This agreement allows them to have new rapid track and trace products for
rapid identification of foodborne contaminants."
Lastly, the FDA will validate and test Life Technologies' next-generation
sequencing technologies for Salmonella investigations as part of its effort to
develop new rapid detection tools that can improve the public health response
to future outbreaks.
Life Technologies has a strong history of combating pathogen outbreaks. In
2011, Life Technologies developed a custom assay to accurately detect the
highly pathogenicE. coli0104:H4 bacterium that spread through Europe,
killing hundreds of people.
"The assay was developed using samples supplied by scientists at University
Hospital Munster, who completed the DNA sequencing and analysis work on the
deadlyE. colistrain using the Ion PGM™ Sequencer," saidManeesh Jain, Ion
Torrent Vice President of Marketing for Life Technologies. "Now the FDA will
validate and test this same technology to understand the molecular
relationship within the Salmonella pathogen in the hopes to prevent future
outbreaks from occurring."
The PGM™ offers scientists the simplest and
fastestworkflow,lowestcost-per-sample,and highest sensitivity formultiple
basic and clinical researchapplications.
About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.
SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.